Weiss Multi-Strategy Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30,000	Closed	-$1.4M	–	586
2017 Q3	$1.4M	Hold	30,000	–	–	0.05%	347
2017 Q2	$1.08M	Hold	30,000	–	–	0.05%	347
2017 Q1	$924K	Buy	30,000 +10,000	+50%	+$311K	0.04%	394
2016 Q4	$670K	Buy	20,000 +10,000	+100%	+$287K	0.03%	308
2016 Q3	$266K	Buy	+10,000	New	+$232K	0.02%	382

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ENTA Position: Q4 2017 in Review

Weiss Multi-Strategy Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q4 2017, closing a stake of 30,000 shares — an estimated $1.4M sold.

Weiss Multi-Strategy Advisers first reported a position in ENTA in Q3 2016 and held it in 5 quarters. The position peaked at $1.4M in Q3 2017. 148 funds tracked by Wall St. Rank hold ENTA as of Q4 2017.

Weiss Multi-Strategy Advisers reported no remaining Enanta Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 30,000 Enanta Pharmaceuticals shares in Q4 2017, an estimated $1.4M.
Weiss Multi-Strategy Advisers first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Weiss Multi-Strategy Advisers's Enanta Pharmaceuticals position peaked at $1.4M in Q3 2017.
148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2017.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.